Active Not Recruiting PHASE1 INTERVENTIONAL 3-arm NCT02293980

A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)

A Phase 1, Multiple-Dose, Dose-Escalation Trial of PT2385 Tablets, a HIF-2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma

Sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Conditions Clear Cell Renal Cell Carcinoma Kidney Cancer RCC Renal Cell Carcinoma ccRCC

Interventions Bezlutifan Cabozantinib MK-3795 Nivolumab

Updated 18 times since 2017 Last updated: Jun 14, 2024 Started: Nov 25, 2014 Primary completion: Jan 31, 2017 Completion: Nov 30, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Clear Cell Renal Cell Carcinoma and Kidney Cancer and is currently ongoing. Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) leads this study, which shows 18 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

18 versions recorded

Sep 2024 — Present [monthly]

Active Not Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE1
May 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE1
Feb 2024 — May 2024 [monthly]

Active Not Recruiting PHASE1
Jan 2024 — Feb 2024 [monthly]

Active Not Recruiting PHASE1

▶ Show 13 earlier versions

Sep 2022 — Jan 2024 [monthly]

Active Not Recruiting PHASE1
Mar 2021 — Sep 2022 [monthly]

Active Not Recruiting PHASE1
Jan 2021 — Mar 2021 [monthly]

Active Not Recruiting PHASE1
Jun 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE1
Apr 2020 — Jun 2020 [monthly]

Active Not Recruiting PHASE1
Dec 2018 — Apr 2020 [monthly]

Active Not Recruiting PHASE1
Jun 2018 — Dec 2018 [monthly]

Active Not Recruiting PHASE1
Sep 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Jul 2017 — Sep 2017 [monthly]

Recruiting PHASE1
Apr 2017 — Jul 2017 [monthly]

Recruiting PHASE1
Mar 2017 — Apr 2017 [monthly]

Recruiting PHASE1
Feb 2017 — Mar 2017 [monthly]

Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1

First recorded

Nov 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Data source: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Aurora, United States , Baltimore, United States , Boston, United States , Chicago, United States , Cleveland, United States , Columbus, United States , Dallas, United States , Detroit, United States , Fairfax, United States and 11 more locations